Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPHCV-1
2015-005004-28Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Nov 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ledipasvir, paritaprevir, dasabuvir, glecaprevir + pibrentasvir and ribavirin in hepatitis C virus infection and chronic hepatitis C (CHC) (2 arms), sponsored by Imperial College London. Primary endpoint: Overall sustained virological response 12 weeks after treatment. Started Nov 2015; status: completed.
02
Drugs
ledipasvirparitaprevirdasabuvirglecaprevir + pibrentasvirribavirin
03
Conditions
hepatitis C virus infectionchronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2015-005004-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005004-28.